Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has Type 2 diabetes~* Currently taking metformin \>1500 mg/day for at least 10 weeks~* Male or female~Exclusion Criteria:~* Patient has peripheral edema~* History of type 1 diabetes~* Patient required insulin within prior 8 weeks~* Have participated or are currently participating in another study with an investigational compound or device within 12 weeks of starting this study~* Participating in a weight loss program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): sitagliptin 100 mg
- Rosiglitazone (Type: ACTIVE_COMPARATOR): rosiglitazone 8 mg
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).